CMRX241018P2000
- 0.00
- 0.000.00%
Chimerix Newsroom
Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Chimerix (CMRX) and Mersana Therapeutics (MRSN)
Analysts Offer Insights on Healthcare Companies: Chimerix (CMRX) and Ocuphire Pharma (OCUP)
Analysts Offer Insights on Healthcare Companies: Werewolf Therapeutics (HOWL) and Chimerix (CMRX)
Capital One Financial Maintains Chimerix(CMRX.US) With Buy Rating, Cuts Target Price to $6
Chimerix Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Chimerix, Maintains $11 Price Target
Buy Rating Justified by Chimerix's Upcoming Catalysts and Strong Financials
Strong Buy Rating for Chimerix on Robust Financials and Promising Drug Pipeline
Chimerix's Strong Financials and Promising ONC201 Developments Merit Buy Rating
Analysts Offer Insights on Healthcare Companies: Chimerix (CMRX), DENTSPLY SIRONA (XRAY) and Karuna Therapeutics (KRTX)
HC Wainwright & Co. Reiterates Buy on Chimerix, Maintains $11 Price Target
Chimerix Analyst Ratings
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Chimerix (CMRX)
Analysts' Top Healthcare Picks: Chimerix (CMRX), MoonLake Immunotherapeutics (MLTX)
Analysts' Top Healthcare Picks: Chimerix (CMRX), ImmunoGen (IMGN)
Analysts Offer Insights on Healthcare Companies: Chimerix (CMRX), Rani Therapeutics Holdings (RANI) and Autolus Therapeutics (AUTL)
Joseph Thome's Buy Rating for Chimerix: An Analysis of Strategic Decision-Making and Potential Growth
JonesTrading Sticks to Their Buy Rating for Chimerix (CMRX)
Chimerix Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Chimerix, Maintains $11 Price Target